A preliminary clinical study in patients also showed that H10 peptide probe-based SPECT imaging could clearly reflect the HER2 status in guiding personalized therapeutic strategies for HER2-positive breast cancer patients [21]. This evidence concerns the gene ERBB2 and breast carcinoma.